WO2003057188A1 - Delivery of caffeine through an inhalation route - Google Patents

Delivery of caffeine through an inhalation route Download PDF

Info

Publication number
WO2003057188A1
WO2003057188A1 PCT/US2002/037489 US0237489W WO03057188A1 WO 2003057188 A1 WO2003057188 A1 WO 2003057188A1 US 0237489 W US0237489 W US 0237489W WO 03057188 A1 WO03057188 A1 WO 03057188A1
Authority
WO
WIPO (PCT)
Prior art keywords
aerosol
caffeine
percent
weight
particles
Prior art date
Application number
PCT/US2002/037489
Other languages
French (fr)
Inventor
Joshua D. Rabinowitz
Original Assignee
Alexza Molecular Delivery Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexza Molecular Delivery Corporation filed Critical Alexza Molecular Delivery Corporation
Priority to EP02798463A priority Critical patent/EP1446102A1/en
Priority to CA002460343A priority patent/CA2460343A1/en
Priority to AU2002363947A priority patent/AU2002363947A1/en
Publication of WO2003057188A1 publication Critical patent/WO2003057188A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Definitions

  • the present invention relates to the delivery of caffeine through an inhalation route. Specifically, it relates to aerosols containing caffeine that are used in inhalation therapy.
  • Caffeine is the most commonly used drug in the world. In moderate doses
  • caffeine is administered either orally or intravenously. These delivery methods have a number of limitations. Peak plasma concentrations following oral administration are generally not reached until 50 to 75 minutes. Intravenous injection, while rapidly delivering the drug, involves the discomfort and risk of infection associated with catheterization or injection.
  • the present invention relates to the delivery of caffeine through an inhalation route. Specifically, it relates to aerosols containing caffeine that are used in inhalation therapy.
  • the aerosol comprises particles comprising at least 5 percent by weight of caffeine.
  • the particles comprise at least 10 percent by weight of caffeine. More preferably, the particles comprise at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent,
  • the aerosol particles comprise less than 10 percent by weight of caffeine degradation products.
  • the particles comprise less than 5 percent by weight of caffeine degradation products. More preferably, the particles comprise less than
  • the aerosol has an inhalable aerosol drug mass density of between
  • the aerosol has an inhalable aerosol drug mass density of between 2 mg/L and 60 mg/L. More preferably, the aerosol has an inhalable aerosol drug mass density of between 3 mg/L and 30 mg/L.
  • the aerosol has an inhalable aerosol particle density greater than
  • the aerosol has an inhalable aerosol particle density greater than 10 7 particles/mL. More preferably, the aerosol has an inhalable aerosol particle density greater than 10 particles/mL.
  • the aerosol particles have a mass median aerodynamic diameter of less than 5 microns.
  • the particles have a mass median aerodynamic diameter of less than 3 microns. More preferably, the particles have a mass median aerodynamic diameter of less than 2 or 1 micron(s).
  • the aerosol is formed by heating a composition containing caffeine to form a vapor and subsequently allowing the vapor to condense into an aerosol.
  • caffeine is delivered to a mammal through an inhalation route.
  • the method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of caffeine; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.
  • the composition that is heated comprises at least 10 percent by weight of caffeine. More preferably, the composition comprises 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent,
  • the delivered aerosol particles comprise at least 5 percent by weight of caffeine.
  • the particles comprise at least 10 percent by weight of caffeine. More preferably, the particles comprise at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent,
  • the delivered aerosol particles comprise less than 10 percent by weight of caffeine degradation products.
  • the particles comprise less than 5 percent by weight of caffeine degradation products. More preferably, the particles comprise less than 2.5, 1, 0.5, 0.1 or 0.03 percent by weight of caffeine degradation products.
  • the particles of the delivered condensation aerosol have a mass median aerodynamic diameter of less than 5 microns.
  • the particles have a mass median aerodynamic diameter of less than 3 microns. More preferably, the particles have a mass median aerodynamic diameter of less than 2 or 1 micron(s).
  • the delivered aerosol has an inhalable aerosol drug mass density of between 1 mg/L and 100 mg/L.
  • the aerosol has an inhalable aerosol drug mass density of between 2 mg/L and 60 mg/L. More preferably, the aerosol has an inhalable aerosol drug mass density of between 3 mg/L and 30 mg/L.
  • the delivered aerosol has an inhalable aerosol particle density greater than 10 6 particles/mL.
  • the aerosol has an inhalable aerosol particle density greater than 10 7 particles/mL. More preferably, the aerosol has an inhalable aerosol particle density greater than 10 8 particles/mL.
  • the rate of inhalable aerosol particle formation of the delivered condensation aerosol is greater than 10 8 particles per second.
  • the aerosol is formed at a rate greater than 10 9 inhalable particles per second or 10 10 inhalable particles per second.
  • the delivered aerosol is formed at a rate greater than 1 mg/second.
  • the aerosol is formed at a rate greater than 5 mg/second. More preferably, the aerosol is formed at a rate greater than 20 mg/second.
  • the condensation aerosol delivers between 1 mg and 100 mg of caffeine to the mammal in a single inspiration. Preferably, between 2 mg and 60 mg of caffeine are delivered to the mammal in a single inspiration. More preferably, between 3 mg and 30 mg of caffeine are delivered to the mammal in a single inspiration.
  • the delivered condensation aerosol results in a peak plasma concentration of caffeine in the mammal in less than 1 h. Preferably, the peak plasma concentration is reached in less than 0.5 h. More preferably, the peak plasma concentration is reached in less than 0.2, 0.1, 0.05, 0.02 or 0.01 h.
  • kits for delivering caffeine through an inhalation route to a mammal which comprises: a) a composition comprising at least 5 percent by weight of caffeine; and, b) a device that forms a caffeine containing aerosol from the composition, for inhalation by the mammal.
  • the composition comprises at least 10 percent by weight of caffeine. More preferably, the composition comprises at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent, 99.9 percent or 99.97 percent by weight of caffeine.
  • the device contained in the kit comprises: a) an element for heating the caffeine composition to form a vapor; b) an element allowing the vapor to cool to form an aerosol; and, c) an element permitting the mammal to inhale the aerosol.
  • Fig. 1 shows a device used to deliver caffeine containing aerosols to a mammal through an inhalation route.
  • Aerodynamic diameter of a given particle refers to the diameter of a spherical droplet with a density of 1 g/mL (the density of water) that has the same settling velocity as the given particle.
  • Alcohol refers to a suspension of solid or liquid particles in a gas.
  • Aerosol drug mass density refers to the mass of caffeine per unit volume of aerosol.
  • Aerosol mass density refers to the mass of particulate matter per unit volume of aerosol.
  • Aerosol particle density refers to the number of particles per unit volume of aerosol.
  • Condensation aerosol refers to an aerosol formed by vaporization of a substance followed by condensation of the substance into an aerosol.
  • Caffeine refers to 3,7-dihydro-l,3,7-trimethyl-lH-purine-2,6-dione, which is a free base.
  • Ciffeine degradation product refers to a compound resulting from a chemical modification of caffeine.
  • the modification for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
  • Inhalable aerosol drug mass density refers to the aerosol drug mass density produced by an inhalation device and delivered into a typical patient tidal volume.
  • Inhalable aerosol mass density refers to the aerosol mass density produced by an inhalation device and delivered into a typical patient tidal volume.
  • Inhalable aerosol particle density refers to the aerosol particle density of particles of size between 100 nm and 5 microns produced by an inhalation device and delivered into a typical patient tidal volume.
  • Mass median aerodynamic diameter or "MMAD” of an aerosol refers to the aerodynamic diameter for which half the particulate mass of the aerosol is contributed by particles with an aerodynamic diameter larger than the MMAD and half by particles with an aerodynamic diameter smaller than the MMAD.
  • Rate of aerosol formation refers to the mass of aerosolized particulate matter produced by an inhalation device per unit time.
  • Rate of inhalable aerosol particle formation refers to the number of particles of size between 100 nm and 5 microns produced by an inhalation device per unit time.
  • Rateate of drug aerosol formation refers to the mass of aerosolized caffeine produced by an inhalation device per unit time.
  • Settling velocity refers to the terminal velocity of an aerosol particle undergoing gravitational settling in air.
  • Typical patient tidal volume refers to 1 L for an adult patient and 15 mL/kg for a pediatric patient.
  • Vapor refers to a gas
  • vapor phase refers to a gas phase
  • thermal vapor refers to a vapor phase, aerosol, or mixture of aerosol- vapor phases, formed preferably by heating.
  • any suitable method is used to form the aerosols of the present invention.
  • a preferred method involves heating a composition comprising caffeine to produce a vapor, followed by cooling of the vapor such that it condenses to provide a caffeine comprising aerosol (condensation aerosol).
  • the composition is heated in one of two forms: as pure active compound ⁇ i.e., pure caffeine); or, as a mixture of active compound and a pharmaceutically acceptable excipient.
  • the composition is heated on a solid support.
  • compositions are either volatile or nonvolatile.
  • Volatile excipients when heated, are concurrently volatilized, aerosolized and inhaled with caffeine.
  • Classes of such excipients are known in the art and include, without limitation, gaseous, supercritical fluid, liquid and solid solvents.
  • Solid supports on which the composition is heated are of a variety of shapes.
  • Examples of such shapes include, without limitation, cylinders of less than 1.0 mm in diameter, boxes of less than 1.0 mm thickness and virtually any shape permeated by small
  • solid supports provide a large surface to volume ratio ⁇ e.g., greater than 100 per meter) and a large surface to mass ratio ⁇ e.g., greater than 1 cm per gram).
  • a solid support of one shape can also be transformed into another shape with different properties.
  • a flat sheet of 0.25 mm thickness has a surface to volume ratio of approximately 8000 per meter. Rolling the sheet into a hollow cylinder of
  • Classes of such materials include, without limitation, metals, inorganic materials, carbonaceous materials and polymers.
  • aluminum foil is a suitable material.
  • silica, alumina and silicon based materials include amphorous silica
  • Chromatography resins such as octadecycl silane chemically bonded to porous silica are exemplary coated variants of silica.
  • the heating of the caffeine compositions is performed using any suitable method.
  • methods by which heat can be generated include the following: passage of current through an electrical resistance element; absorption of electromagnetic radiation, such as microwave or laser light; and, exothermic chemical reactions, such as exothermic solvation, hydration of pyrophoric materials and oxidation of combustible materials.
  • Caffeine containing aerosols of the present invention are delivered to a mammal using an inhalation device.
  • the aerosol is a condensation aerosol
  • the device has at least three elements: an element for heating a caffeine containing composition to form a vapor; an element allowing the vapor to cool, thereby providing a condensation aerosol; and, an element permitting the mammal to inhale the aerosol.
  • the element that allows cooling is, in it simplest form, an inert passageway linking the heating means to the inhalation means.
  • the element permitting inhalation is an aerosol exit portal that forms a connection between the cooling element and the mammal's respiratory system.
  • Delivery device 100 has a proximal end 102 and a distal end 104, a heating module 106, a power source 108, and a mouthpiece 110.
  • a caffeine composition is deposited on a surface 112 of heating module 106.
  • power source 108 initiates heating of heating module 106 ⁇ e.g, through ignition of combustible fuel or passage of current through a resistive heating element).
  • the caffeine composition volatilizes due to the heating of heating module 106 and condenses to form a condensation aerosol prior to reaching the mouthpiece 110 at the proximal end of the device 102.
  • Devices contain a variety of components to facilitate the delivery of caffeine containing aerosols.
  • the device may include any component known in the art to control the timing of drug aerosolization relative to inhalation ⁇ e.g., breath-actuation), to provide feedback to patients on the rate and/or volume of inhalation, to prevent excessive use ⁇ i.e., "lock-out” feature), to prevent use by unauthorized individuals, and/or to record dosing histories.
  • Dosage of Caffeine Containing Aerosols may include any component known in the art to control the timing of drug aerosolization relative to inhalation ⁇ e.g., breath-actuation), to provide feedback to patients on the rate and/or volume of inhalation, to prevent excessive use ⁇ i.e., "lock-out” feature), to prevent use by unauthorized individuals, and/or to record dosing histories.
  • caffeine is given orally at doses between 30 mg and 100 mg, generally in combination with another active compound ⁇ e.g., aspirin or ergotamine, respectively).
  • another active compound e.g., aspirin or ergotamine, respectively.
  • As an aerosol between 3 and 30 mg of caffeine is generally provided per inspiration for these indications.
  • a typical dosage of a caffeine aerosol is either administered as a single inhalation or as a series of inhalations taken within an hour or less (dosage equals sum of inhaled amounts). Where the drug is administered as a series of inhalations, a different amount may be delivered in each inhalation.
  • the dosage amount of caffeine in aerosol form is generally no greater than twice the standard dose of the drug given through other methods.
  • One animal experiment involves measuring plasma concentrations of drug in an animal after its exposure to the aerosol. Mammals such as dogs or primates are typically used in such studies, since their respiratory systems are similar to that of a human.
  • Initial dose levels for testing in humans are generally less than or equal to the dose in the mammal model that resulted in plasma drug levels associated with a therapeutic effect in humans. Dose escalation in humans is then performed, until either an optimal therapeutic response is obtained or a dose-limiting toxicity is encountered.
  • Purity of a caffeine containing aerosol is determined using a number of methods, examples of which are described in Sekine et al, Journal of Forensic Science 32:1271-1280 (1987) and Martin et al, Journal of Analytic Toxicology 13:158-162 (1989).
  • One method involves forming the aerosol in a device through which a gas flow ⁇ e.g., air flow) is maintained, generally at a rate between 0.4 and 60 L/min.
  • the gas flow carries the aerosol into one or more traps.
  • the aerosol is subjected to an analytical technique, such as gas or liquid chromatography, that permits a determination of composition purity.
  • a variety of different traps are used for aerosol collection.
  • the following list contains examples of such traps: filters; glass wool; impingers; solvent traps, such as dry ice-cooled ethanol, methanol, acetone and dichloromethane traps at various pH values; syringes that sample the aerosol; empty, low-pressure (e.g., vacuum) containers into which the aerosol is drawn; and, empty containers that fully surround and enclose the aerosol generating device.
  • a solid such as glass wool
  • it is typically extracted with a solvent such as ethanol.
  • the solvent extract is subjected to analysis rather than the solid ⁇ i.e., glass wool) itself.
  • the container is similarly extracted with a solvent.
  • the gas or liquid chromatograph discussed above contains a detection system ⁇ i.e., detector).
  • detection systems are well known in the art and include, for example, flame ionization, photon absorption and mass spectrometry detectors.
  • An advantage of a mass spectrometry detector is that it can be used to determine the structure of caffeine degradation products.
  • Particle size distribution of a caffeine containing aerosol is determined using any suitable method in the art ⁇ e.g., cascade impaction).
  • An Andersen Eight Stage Non- viable Cascade Impactor (Andersen Instruments, Smyrna, GA) linked to a furnace tube by a mock throat (USP throat, Andersen Instruments, Smyrna, GA) is one system used for cascade impaction studies.
  • Inhalable aerosol mass density is determined, for example, by delivering a drug-containing aerosol into a confined chamber via an inhalation device and measuring the mass collected in the chamber.
  • the aerosol is drawn into the chamber by having a pressure gradient between the device and the chamber, wherein the chamber is at lower pressure than the device.
  • the volume of the chamber should approximate the tidal volume of an inhaling patient.
  • Inhalable aerosol drug mass density is determined, for example, by delivering a drug-containing aerosol into a confined chamber via an inhalation device and measuring the amount of active drug compound collected in the chamber.
  • the aerosol is drawn into the chamber by having a pressure gradient between the device and the chamber, wherein the chamber is at lower pressure than the device.
  • the volume of the chamber should approximate the tidal volume of an inhaling patient.
  • the amount of active drug compound collected in the chamber is determined by extracting the chamber, conducting chromatographic analysis of the extract and comparing the results of the chromatographic analysis to those of a standard containing known amounts of drug.
  • Inhalable aerosol particle density is determined, for example, by delivering aerosol phase drug into a confined chamber via an inhalation device and measuring the number of particles of given size collected in the chamber.
  • the number of particles of a given size may be directly measured based on the light-scattering properties of the particles.
  • Rate of inhalable aerosol particle formation is determined, for example, by delivering aerosol phase drug into a confined chamber via an inhalation device. The delivery is for a set period of time ⁇ e.g., 3 s), and the number of particles of a given size collected in the chamber is determined as outlined above. The rate of particle formation is equal to the number of 100 nm to 5 micron particles collected divided by the duration of the collection time.
  • Rate of aerosol formation is determined, for example, by delivering aerosol phase drug into a confined chamber via an inhalation device.
  • the delivery is for a set period of time ⁇ e.g., 3 s), and the mass of particulate matter collected is determined by weighing the confined chamber before and after the delivery of the particulate matter.
  • the rate of aerosol formation is equal to the increase in mass in the chamber divided by the duration of the collection time.
  • the mass of particulate matter may be equated with the mass lost from the device or component during the delivery of the aerosol.
  • the rate of aerosol formation is equal to the decrease in mass of the device or component during the delivery event divided by the duration of the delivery event.
  • Rate of drug aerosol formation is determined, for example, by delivering a caffeine containing aerosol into a confined chamber via an inhalation device over a set period of time ⁇ e.g., 3 s). Where the aerosol is pure caffeine, the amount of drug collected in the chamber is measured as described above. The rate of drug aerosol formation is equal to the amount of caffeine collected in the chamber divided by the duration of the collection time. Where the caffeine containing aerosol comprises a pharmaceutically acceptable excipient, multiplying the rate of aerosol formation by the percentage of caffeine in the aerosol provides the rate of drug aerosol formation.
  • caffeine aerosols of the present invention respiratory stimulation; acute treatment of fatigue; enhancement of alertness; treatment of narcolepsy; induction of a positive state of mind; analgesia; treatment of nicotine craving; treatment of cocaine and other elicit drug craving; and, treatment of headache, including without limitation, tension headache, migraine headache and headache due to leakage of cerebrospinal fluid.
  • Caffeine is commercially available from Sigma (www.sigma-aldrich.com).
  • a furnace tube was connected to a vacuum outlet. In between the tube and the outlet was placed a glass wool plug. The furnace tube was preheated to 300 °C. Caffeine (82 mg) was added to the preheated tube, and an air flow rate of 2 L/min was applied using the vacuum. After 2 min, the furnace tube was allowed to cool. The walls of the tube outside of the heating zone and the glass wool were extracted with solvent. Analysis of the extract showed that approximately 40% of the caffeine had volatilized at a purity level >99%.

Abstract

The present invention relates to the delivery of caffeine through an inhalation route. Specifically, it relates to aerosols containing caffeine that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of caffeine. In a method aspect of the present invention, caffeine is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of caffeine, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. In a kit aspect of the present invention, a kit for delivering caffeine through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of caffeine; and, b) a device that forms a caffeine containing aerosol from the composition, for inhalation by the mammal.

Description

DELIVERY OF CAFFEINE THROUGH AN INHALATION ROUTE
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. provisional application Serial No.
60/332,279 entitled "Delivery of Caffeine through an Inhalation Route," filed November 21, 2001, Joshua D. Rabinowitz, the entire disclosure of which is hereby incorporated by reference.
FIELD OF THE INVENTION
[0002] The present invention relates to the delivery of caffeine through an inhalation route. Specifically, it relates to aerosols containing caffeine that are used in inhalation therapy.
BACKGROUND OF THE INVENTION
[0003] Caffeine is the most commonly used drug in the world. In moderate doses
(75-150 mg), it elevates neural activity in many parts of the brain, postpones fatigue, and enhances performance of simple intellectual tasks and physical work that involves endurance. The most common therapeutic use of caffeine is to relieve pain, especially headache pain, although it is also a mild diuretic and a respiratory stimulant. [0004] Typically, caffeine is administered either orally or intravenously. These delivery methods have a number of limitations. Peak plasma concentrations following oral administration are generally not reached until 50 to 75 minutes. Intravenous injection, while rapidly delivering the drug, involves the discomfort and risk of infection associated with catheterization or injection.
[0005] It is desirable to provide a new route of administration for caffeine that allows for the rapid acquisition of peak plasma concentrations without the disadvantages of catheterization or injection. The provision of such a route is an object of the present invention. SUMMARY OF THE INVENTION
[0006] The present invention relates to the delivery of caffeine through an inhalation route. Specifically, it relates to aerosols containing caffeine that are used in inhalation therapy.
[0007] In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of caffeine. Preferably, the particles comprise at least 10 percent by weight of caffeine. More preferably, the particles comprise at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent,
90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent or 99.97 percent by weight of caffeine.
[0008] Typically, the aerosol particles comprise less than 10 percent by weight of caffeine degradation products. Preferably, the particles comprise less than 5 percent by weight of caffeine degradation products. More preferably, the particles comprise less than
2.5, 1, 0.5, 0.1 or 0.03 percent by weight of caffeine degradation products.
[0009] Typically, the aerosol has an inhalable aerosol drug mass density of between
1 mg/L and 100 mg L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 2 mg/L and 60 mg/L. More preferably, the aerosol has an inhalable aerosol drug mass density of between 3 mg/L and 30 mg/L.
[0010] Typically, the aerosol has an inhalable aerosol particle density greater than
106 particles/mL. Preferably, the aerosol has an inhalable aerosol particle density greater than 107 particles/mL. More preferably, the aerosol has an inhalable aerosol particle density greater than 10 particles/mL.
[0011] Typically, the aerosol particles have a mass median aerodynamic diameter of less than 5 microns. Preferably, the particles have a mass median aerodynamic diameter of less than 3 microns. More preferably, the particles have a mass median aerodynamic diameter of less than 2 or 1 micron(s).
[0012] Typically, the aerosol is formed by heating a composition containing caffeine to form a vapor and subsequently allowing the vapor to condense into an aerosol.
[0013] In a method aspect of the present invention, caffeine is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of caffeine; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal. Preferably, the composition that is heated comprises at least 10 percent by weight of caffeine. More preferably, the composition comprises 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent,
95 percent, 97 percent, 99 percent, 99.5 percent, 99.9 percent or 99.97 percent by weight of caffeine.
[0014] Typically, the delivered aerosol particles comprise at least 5 percent by weight of caffeine. Preferably, the particles comprise at least 10 percent by weight of caffeine. More preferably, the particles comprise at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent,
99 percent, 99.5 percent, 99.9 percent or 99.97 percent by weight of caffeine.
[0015] Typically, the delivered aerosol particles comprise less than 10 percent by weight of caffeine degradation products. Preferably, the particles comprise less than 5 percent by weight of caffeine degradation products. More preferably, the particles comprise less than 2.5, 1, 0.5, 0.1 or 0.03 percent by weight of caffeine degradation products.
[0016] Typically, the particles of the delivered condensation aerosol have a mass median aerodynamic diameter of less than 5 microns. Preferably, the particles have a mass median aerodynamic diameter of less than 3 microns. More preferably, the particles have a mass median aerodynamic diameter of less than 2 or 1 micron(s).
[0017] Typically, the delivered aerosol has an inhalable aerosol drug mass density of between 1 mg/L and 100 mg/L. Preferably, the aerosol has an inhalable aerosol drug mass density of between 2 mg/L and 60 mg/L. More preferably, the aerosol has an inhalable aerosol drug mass density of between 3 mg/L and 30 mg/L.
[0018] Typically, the delivered aerosol has an inhalable aerosol particle density greater than 106 particles/mL. Preferably, the aerosol has an inhalable aerosol particle density greater than 107 particles/mL. More preferably, the aerosol has an inhalable aerosol particle density greater than 108 particles/mL.
[0019] Typically, the rate of inhalable aerosol particle formation of the delivered condensation aerosol is greater than 108 particles per second. Preferably, the aerosol is formed at a rate greater than 109 inhalable particles per second or 1010 inhalable particles per second.
[0020] Typically, the delivered aerosol is formed at a rate greater than 1 mg/second.
Preferably, the aerosol is formed at a rate greater than 5 mg/second. More preferably, the aerosol is formed at a rate greater than 20 mg/second. [0021] Typically, the condensation aerosol delivers between 1 mg and 100 mg of caffeine to the mammal in a single inspiration. Preferably, between 2 mg and 60 mg of caffeine are delivered to the mammal in a single inspiration. More preferably, between 3 mg and 30 mg of caffeine are delivered to the mammal in a single inspiration. [0022] Typically, the delivered condensation aerosol results in a peak plasma concentration of caffeine in the mammal in less than 1 h. Preferably, the peak plasma concentration is reached in less than 0.5 h. More preferably, the peak plasma concentration is reached in less than 0.2, 0.1, 0.05, 0.02 or 0.01 h.
[0023] In a kit aspect of the present invention, a kit for delivering caffeine through an inhalation route to a mammal is provided which comprises: a) a composition comprising at least 5 percent by weight of caffeine; and, b) a device that forms a caffeine containing aerosol from the composition, for inhalation by the mammal. Preferably, the composition comprises at least 10 percent by weight of caffeine. More preferably, the composition comprises at least 20 percent, 30 percent, 40 percent, 50 percent, 60 percent, 70 percent, 80 percent, 90 percent, 95 percent, 97 percent, 99 percent, 99.5 percent, 99.9 percent or 99.97 percent by weight of caffeine.
[0024] Typically, the device contained in the kit comprises: a) an element for heating the caffeine composition to form a vapor; b) an element allowing the vapor to cool to form an aerosol; and, c) an element permitting the mammal to inhale the aerosol.
BRIEF DESCRIPTION OF THE FIGURE
[0025] Fig. 1 shows a device used to deliver caffeine containing aerosols to a mammal through an inhalation route.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0026] "Aerodynamic diameter" of a given particle refers to the diameter of a spherical droplet with a density of 1 g/mL (the density of water) that has the same settling velocity as the given particle.
[0027] "Aerosol" refers to a suspension of solid or liquid particles in a gas.
[0028] "Aerosol drug mass density" refers to the mass of caffeine per unit volume of aerosol. [0029] "Aerosol mass density" refers to the mass of particulate matter per unit volume of aerosol.
[0030] "Aerosol particle density" refers to the number of particles per unit volume of aerosol.
[0031] "Condensation aerosol" refers to an aerosol formed by vaporization of a substance followed by condensation of the substance into an aerosol.
[0032] "Caffeine" refers to 3,7-dihydro-l,3,7-trimethyl-lH-purine-2,6-dione, which is a free base.
[0033] "Caffeine" degradation product refers to a compound resulting from a chemical modification of caffeine. The modification, for example, can be the result of a thermally or photochemically induced reaction. Such reactions include, without limitation, oxidation and hydrolysis.
[0034] "Inhalable aerosol drug mass density" refers to the aerosol drug mass density produced by an inhalation device and delivered into a typical patient tidal volume.
[0035] "Inhalable aerosol mass density" refers to the aerosol mass density produced by an inhalation device and delivered into a typical patient tidal volume.
[0036] "Inhalable aerosol particle density" refers to the aerosol particle density of particles of size between 100 nm and 5 microns produced by an inhalation device and delivered into a typical patient tidal volume.
[0037] "Mass median aerodynamic diameter" or "MMAD" of an aerosol refers to the aerodynamic diameter for which half the particulate mass of the aerosol is contributed by particles with an aerodynamic diameter larger than the MMAD and half by particles with an aerodynamic diameter smaller than the MMAD.
[0038] "Rate of aerosol formation" refers to the mass of aerosolized particulate matter produced by an inhalation device per unit time.
[0039] "Rate of inhalable aerosol particle formation" refers to the number of particles of size between 100 nm and 5 microns produced by an inhalation device per unit time.
[0040] "Rate of drug aerosol formation" refers to the mass of aerosolized caffeine produced by an inhalation device per unit time.
[0041] "Settling velocity" refers to the terminal velocity of an aerosol particle undergoing gravitational settling in air. [0042] "Typical patient tidal volume" refers to 1 L for an adult patient and 15 mL/kg for a pediatric patient.
[0043] "Vapor" refers to a gas, and "vapor phase" refers to a gas phase. The term
"thermal vapor" refers to a vapor phase, aerosol, or mixture of aerosol- vapor phases, formed preferably by heating.
Formation of Caffeine Containing Aerosols
[0044] Any suitable method is used to form the aerosols of the present invention. A preferred method, however, involves heating a composition comprising caffeine to produce a vapor, followed by cooling of the vapor such that it condenses to provide a caffeine comprising aerosol (condensation aerosol). The composition is heated in one of two forms: as pure active compound {i.e., pure caffeine); or, as a mixture of active compound and a pharmaceutically acceptable excipient. Typically, the composition is heated on a solid support.
[0045] Pharmaceutically acceptable excipients are either volatile or nonvolatile.
Volatile excipients, when heated, are concurrently volatilized, aerosolized and inhaled with caffeine. Classes of such excipients are known in the art and include, without limitation, gaseous, supercritical fluid, liquid and solid solvents. The following is a list of exemplary carriers within the classes: water; terpenes, such as menthol; alcohols, such as ethanol, propylene glycol, glycerol and other similar alcohols; dimethylformamide; dimethylacetamide; wax; supercritical carbon dioxide; dry ice; and mixtures thereof.
[0046] Solid supports on which the composition is heated are of a variety of shapes.
Examples of such shapes include, without limitation, cylinders of less than 1.0 mm in diameter, boxes of less than 1.0 mm thickness and virtually any shape permeated by small
{e.g., less than 1.0 mm-sized) pores. Preferably, solid supports provide a large surface to volume ratio {e.g., greater than 100 per meter) and a large surface to mass ratio {e.g., greater than 1 cm per gram).
[0047] A solid support of one shape can also be transformed into another shape with different properties. For example, a flat sheet of 0.25 mm thickness has a surface to volume ratio of approximately 8000 per meter. Rolling the sheet into a hollow cylinder of
1 cm diameter produces a support that retains the high surface to mass ratio of the original sheet but has a lower surface to volume ratio (about 400 per meter).
[0048] A number of different materials are used to construct the solid supports.
Classes of such materials include, without limitation, metals, inorganic materials, carbonaceous materials and polymers. The following are examples of the material classes: aluminum, silver, gold, stainless steel, copper and tungsten; silica, glass, silicon and alumina; graphite, porous carbons, carbon yarns and carbon felts; polytetrafluoroethylene and polyethylene glycol. Combinations of materials and coated variants of materials are used as well.
[0049] Where aluminum is used as a solid support, aluminum foil is a suitable material. Examples of silica, alumina and silicon based materials include amphorous silica
S-5631 (Sigma, St. Louis, MO), BCR171 (an alumina of defined surface area greater than 2 m2/g from Aldrich, St. Louis, MO) and a silicon wafer as used in the semiconductor industry. Carbon yarns and felts are available from American Kynol, Inc., New York, NY.
Chromatography resins such as octadecycl silane chemically bonded to porous silica are exemplary coated variants of silica.
[0050] The heating of the caffeine compositions is performed using any suitable method. Examples of methods by which heat can be generated include the following: passage of current through an electrical resistance element; absorption of electromagnetic radiation, such as microwave or laser light; and, exothermic chemical reactions, such as exothermic solvation, hydration of pyrophoric materials and oxidation of combustible materials.
Delivery of Caffeine Containing Aerosols
[0051] Caffeine containing aerosols of the present invention are delivered to a mammal using an inhalation device. Where the aerosol is a condensation aerosol, the device has at least three elements: an element for heating a caffeine containing composition to form a vapor; an element allowing the vapor to cool, thereby providing a condensation aerosol; and, an element permitting the mammal to inhale the aerosol.
Various suitable heating methods are described above. The element that allows cooling is, in it simplest form, an inert passageway linking the heating means to the inhalation means.
The element permitting inhalation is an aerosol exit portal that forms a connection between the cooling element and the mammal's respiratory system.
[0052] One device used to deliver caffeine containing aerosol is described in reference to Fig. 1. Delivery device 100 has a proximal end 102 and a distal end 104, a heating module 106, a power source 108, and a mouthpiece 110. A caffeine composition is deposited on a surface 112 of heating module 106. Upon activation of a user activated switch 114, power source 108 initiates heating of heating module 106 {e.g, through ignition of combustible fuel or passage of current through a resistive heating element). The caffeine composition volatilizes due to the heating of heating module 106 and condenses to form a condensation aerosol prior to reaching the mouthpiece 110 at the proximal end of the device 102. Air flow traveling from the device distal end 104 to the mouthpiece 110 carries the condensation aerosol to the mouthpiece 110, where it is inhaled by the mammal. [0053] Devices, if desired, contain a variety of components to facilitate the delivery of caffeine containing aerosols. For instance, the device may include any component known in the art to control the timing of drug aerosolization relative to inhalation {e.g., breath-actuation), to provide feedback to patients on the rate and/or volume of inhalation, to prevent excessive use {i.e., "lock-out" feature), to prevent use by unauthorized individuals, and/or to record dosing histories. Dosage of Caffeine Containing Aerosols
[0054] For analgesis effect or the relief of migraine headache, caffeine is given orally at doses between 30 mg and 100 mg, generally in combination with another active compound {e.g., aspirin or ergotamine, respectively). As an aerosol, between 3 and 30 mg of caffeine is generally provided per inspiration for these indications. A typical dosage of a caffeine aerosol is either administered as a single inhalation or as a series of inhalations taken within an hour or less (dosage equals sum of inhaled amounts). Where the drug is administered as a series of inhalations, a different amount may be delivered in each inhalation. The dosage amount of caffeine in aerosol form is generally no greater than twice the standard dose of the drug given through other methods. [0055] One can determine the appropriate dose of a caffeine containing aerosol to treat a particular condition using methods such as animal experiments and a dose-finding (Phase I/II) clinical trial. One animal experiment involves measuring plasma concentrations of drug in an animal after its exposure to the aerosol. Mammals such as dogs or primates are typically used in such studies, since their respiratory systems are similar to that of a human. Initial dose levels for testing in humans are generally less than or equal to the dose in the mammal model that resulted in plasma drug levels associated with a therapeutic effect in humans. Dose escalation in humans is then performed, until either an optimal therapeutic response is obtained or a dose-limiting toxicity is encountered. Analysis of Caffeine Containing Aerosols [0056] Purity of a caffeine containing aerosol is determined using a number of methods, examples of which are described in Sekine et al, Journal of Forensic Science 32:1271-1280 (1987) and Martin et al, Journal of Analytic Toxicology 13:158-162 (1989). One method involves forming the aerosol in a device through which a gas flow {e.g., air flow) is maintained, generally at a rate between 0.4 and 60 L/min. The gas flow carries the aerosol into one or more traps. After isolation from the trap, the aerosol is subjected to an analytical technique, such as gas or liquid chromatography, that permits a determination of composition purity.
[0057] A variety of different traps are used for aerosol collection. The following list contains examples of such traps: filters; glass wool; impingers; solvent traps, such as dry ice-cooled ethanol, methanol, acetone and dichloromethane traps at various pH values; syringes that sample the aerosol; empty, low-pressure (e.g., vacuum) containers into which the aerosol is drawn; and, empty containers that fully surround and enclose the aerosol generating device. Where a solid such as glass wool is used, it is typically extracted with a solvent such as ethanol. The solvent extract is subjected to analysis rather than the solid {i.e., glass wool) itself. Where a syringe or container is used, the container is similarly extracted with a solvent.
[0058] The gas or liquid chromatograph discussed above contains a detection system {i.e., detector). Such detection systems are well known in the art and include, for example, flame ionization, photon absorption and mass spectrometry detectors. An advantage of a mass spectrometry detector is that it can be used to determine the structure of caffeine degradation products.
[0059] Particle size distribution of a caffeine containing aerosol is determined using any suitable method in the art {e.g., cascade impaction). An Andersen Eight Stage Non- viable Cascade Impactor (Andersen Instruments, Smyrna, GA) linked to a furnace tube by a mock throat (USP throat, Andersen Instruments, Smyrna, GA) is one system used for cascade impaction studies.
[0060] Inhalable aerosol mass density is determined, for example, by delivering a drug-containing aerosol into a confined chamber via an inhalation device and measuring the mass collected in the chamber. Typically, the aerosol is drawn into the chamber by having a pressure gradient between the device and the chamber, wherein the chamber is at lower pressure than the device. The volume of the chamber should approximate the tidal volume of an inhaling patient. [0061] Inhalable aerosol drug mass density is determined, for example, by delivering a drug-containing aerosol into a confined chamber via an inhalation device and measuring the amount of active drug compound collected in the chamber. Typically, the aerosol is drawn into the chamber by having a pressure gradient between the device and the chamber, wherein the chamber is at lower pressure than the device. The volume of the chamber should approximate the tidal volume of an inhaling patient. The amount of active drug compound collected in the chamber is determined by extracting the chamber, conducting chromatographic analysis of the extract and comparing the results of the chromatographic analysis to those of a standard containing known amounts of drug.
[0062] Inhalable aerosol particle density is determined, for example, by delivering aerosol phase drug into a confined chamber via an inhalation device and measuring the number of particles of given size collected in the chamber. The number of particles of a given size may be directly measured based on the light-scattering properties of the particles. Alternatively, the number of particles of a given size may be determined by measuring the mass of particles within the given size range and calculating the number of particles based on the mass as follows: Total number of particles = Sum (from size range
1 to size range N) of number of particles in each size range. Number of particles in a given size range = Mass in the size range/Mass of a typical particle in the size range. Mass of a typical particle in a given size range = π*D *φ/6, where D is a typical particle diameter in the size range (generally, the mean of the boundary MMADs defining the size range) in microns, φ is the particle density (in g/mL) and mass is given in units of picograms (g"12).
[0063] Rate of inhalable aerosol particle formation is determined, for example, by delivering aerosol phase drug into a confined chamber via an inhalation device. The delivery is for a set period of time {e.g., 3 s), and the number of particles of a given size collected in the chamber is determined as outlined above. The rate of particle formation is equal to the number of 100 nm to 5 micron particles collected divided by the duration of the collection time.
[0064] Rate of aerosol formation is determined, for example, by delivering aerosol phase drug into a confined chamber via an inhalation device. The delivery is for a set period of time {e.g., 3 s), and the mass of particulate matter collected is determined by weighing the confined chamber before and after the delivery of the particulate matter. The rate of aerosol formation is equal to the increase in mass in the chamber divided by the duration of the collection time. Alternatively, where a change in mass of the delivery device or component thereof can only occur through release of the aerosol phase particulate matter, the mass of particulate matter may be equated with the mass lost from the device or component during the delivery of the aerosol. In this case, the rate of aerosol formation is equal to the decrease in mass of the device or component during the delivery event divided by the duration of the delivery event.
[0065] Rate of drug aerosol formation is determined, for example, by delivering a caffeine containing aerosol into a confined chamber via an inhalation device over a set period of time {e.g., 3 s). Where the aerosol is pure caffeine, the amount of drug collected in the chamber is measured as described above. The rate of drug aerosol formation is equal to the amount of caffeine collected in the chamber divided by the duration of the collection time. Where the caffeine containing aerosol comprises a pharmaceutically acceptable excipient, multiplying the rate of aerosol formation by the percentage of caffeine in the aerosol provides the rate of drug aerosol formation.
Utility of Caffeine Containing Aerosols
[0066] The following are typical uses for caffeine aerosols of the present invention: respiratory stimulation; acute treatment of fatigue; enhancement of alertness; treatment of narcolepsy; induction of a positive state of mind; analgesia; treatment of nicotine craving; treatment of cocaine and other elicit drug craving; and, treatment of headache, including without limitation, tension headache, migraine headache and headache due to leakage of cerebrospinal fluid.
[0067] The following examples are meant to illustrate, rather than limit, the present invention.
[0068] Caffeine is commercially available from Sigma (www.sigma-aldrich.com).
EXAMPLE 1
Volatilization of Caffeine [0069] A furnace tube was connected to a vacuum outlet. In between the tube and the outlet was placed a glass wool plug. The furnace tube was preheated to 300 °C. Caffeine (82 mg) was added to the preheated tube, and an air flow rate of 2 L/min was applied using the vacuum. After 2 min, the furnace tube was allowed to cool. The walls of the tube outside of the heating zone and the glass wool were extracted with solvent. Analysis of the extract showed that approximately 40% of the caffeine had volatilized at a purity level >99%.
EXAMPLE 2
Particle Size of Caffeine Aerosol [0070] An Andersen Eight Stage Non- viable Cascade Impactor (Andersen
Instruments, Smyrna, GA) was linked to a furnace tube by a mock throat (USP throat, Andersen Instruments, Smyrna, GA) for cascade impaction studies. The furnace tube was preheated to 350 °C. To the preheated tube was added 100 mg caffeine. After 15 s, an air flow of 28 L/min was applied for 2 min. The tube was allowed to cool, and the results from the cascade impactor were analyzed (see Table 1). MMAD of the collected aerosol was 1.1 microns with a geometric standard deviation of 3.
Table 1 determination of the particle size of a caffeine condensation aerosol by cascade impaction using an Andersen 8 -stage non-viable cascade impactor.
Figure imgf000014_0001

Claims

1. An aerosol comprising particles, wherein the particles comprise at least 5 percent by weight of caffeine.
2. The aerosol according to Claim 1 , wherein the particles comprise at least 95 percent by weight of caffeine.
3. The aerosol according to Claim 1, wherein the particles comprise at least 97 percent by weight of caffeine.
4. The aerosol according to Claim 3, wherein the aerosol comprises less than 1 percent by weight of caffeine degradation products.
5. The aerosol according to Claim 3, wherein the aerosol has an inhalable aerosol drug mass density of between 3 mg/L and 30 mg/L.
6. The aerosol according to Claim 3, wherein the aerosol has an inhalable aerosol particle density greater than 10 particles/mL.
7. The aerosol according to Claim 3, wherein the particles have a mass median aerodynamic diameter less than 2.
8. The aerosol according to Claim 3, wherein the aerosol is formed by heating a composition containing caffeine to form a vapor, which subsequently condenses to form an aerosol.
9. A method for delivering caffeine to a mammal through an inhalation route, wherein the method comprises:
(a) heating a composition, wherein the composition comprises at least 5 percent by weight of caffeine to form a vapor; and,
(b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles which is inhaled by the mammal.
10. The method according to Claim 9, wherein the aerosol comprises at least 95 percent by weight of caffeine.
11. The method according to Claim 9, wherein the aerosol comprises at least 97 percent by weight of caffeine.
12. The method according to Claim 11, wherein the aerosol particles comprise less than 1 percent by weight of caffeine degradation products.
13. A kit for delivering caffeine through an inhalation route to a mammal, wherein the kit comprises: a) a composition comprising at least 5 percent by weight of caffeine; and, b) a device that forms a caffeine containing aerosol from the composition for inhalation by the mammal.
14. The kit according to Claim 13, wherein the composition comprises at least 90 percent by weight of caffeine.
15. The kit according to Claim 14, wherein the device contained in the kit comprises: a) an element for heating the caffeine composition to form a vapor; b) an element allowing the vapor to cool to form an aerosol; and, c) an element permitting the mammal to inhale the aerosol.
PCT/US2002/037489 2001-11-21 2002-11-21 Delivery of caffeine through an inhalation route WO2003057188A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02798463A EP1446102A1 (en) 2001-11-21 2002-11-21 Delivery of caffeine through an inhalation route
CA002460343A CA2460343A1 (en) 2001-11-21 2002-11-21 Delivery of caffeine through an inhalation route
AU2002363947A AU2002363947A1 (en) 2001-11-21 2002-11-21 Delivery of caffeine through an inhalation route

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33227901P 2001-11-21 2001-11-21
US60/332,279 2001-11-21

Publications (1)

Publication Number Publication Date
WO2003057188A1 true WO2003057188A1 (en) 2003-07-17

Family

ID=23297533

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/037489 WO2003057188A1 (en) 2001-11-21 2002-11-21 Delivery of caffeine through an inhalation route

Country Status (5)

Country Link
US (2) US7078016B2 (en)
EP (1) EP1446102A1 (en)
AU (1) AU2002363947A1 (en)
CA (1) CA2460343A1 (en)
WO (1) WO2003057188A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081431A1 (en) * 2006-11-13 2009-07-29 Intra-Cellular Therapies, Inc. Organic compounds
WO2013006809A3 (en) * 2011-07-06 2013-06-13 Breathable Foods, Inc. Aerosolizing particles
WO2015006465A1 (en) * 2013-07-10 2015-01-15 Ahkeo Ventures LLC Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
WO2003094900A1 (en) * 2002-05-13 2003-11-20 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
US20060193788A1 (en) * 2002-11-26 2006-08-31 Hale Ron L Acute treatment of headache with phenothiazine antipsychotics
JP2006514934A (en) 2002-11-26 2006-05-18 アレックザ ファーマシューティカルズ， インコーポレイテッド Use of loxapine or amoxapine for the manufacture of drugs for the treatment of pain
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
JP2007516404A (en) 2003-05-21 2007-06-21 アレックザ ファーマシューティカルズ， インコーポレイテッド Optically or electrically ignited built-in heating unit and drug supply unit using the same
CA2534566A1 (en) * 2003-08-04 2005-02-24 Alexza Pharmaceuticals, Inc. Substrates for drug delivery device and methods of preparing and use
US7785619B2 (en) * 2004-04-08 2010-08-31 Micro Nutrient, Llc Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens
US20050226906A1 (en) * 2004-04-08 2005-10-13 Micro Nutrient, Llc Nutrient system for individualized responsive dosing regimens
US7402777B2 (en) * 2004-05-20 2008-07-22 Alexza Pharmaceuticals, Inc. Stable initiator compositions and igniters
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20100006092A1 (en) * 2004-08-12 2010-01-14 Alexza Pharmaceuticals, Inc. Aerosol Drug Delivery Device Incorporating Percussively Activated Heat Packages
KR100857596B1 (en) * 2005-08-23 2008-09-09 삼성전자주식회사 Nano particle generator
US20080299048A1 (en) * 2006-12-22 2008-12-04 Alexza Pharmaceuticals, Inc. Mixed drug aerosol compositions
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US7834295B2 (en) 2008-09-16 2010-11-16 Alexza Pharmaceuticals, Inc. Printable igniters
US20100065052A1 (en) * 2008-09-16 2010-03-18 Alexza Pharmaceuticals, Inc. Heating Units
US20100300433A1 (en) * 2009-05-28 2010-12-02 Alexza Pharmaceuticals, Inc. Substrates for Enhancing Purity or Yield of Compounds Forming a Condensation Aerosol
US20120048963A1 (en) 2010-08-26 2012-03-01 Alexza Pharmaceuticals, Inc. Heat Units Using a Solid Fuel Capable of Undergoing an Exothermic Metal Oxidation-Reduction Reaction Propagated without an Igniter
JP6397493B2 (en) 2013-07-11 2018-09-26 アレックザ ファーマシューティカルズ， インコーポレイテッド Nicotine salt with meta-salicylic acid
US9962369B2 (en) 2014-03-10 2018-05-08 Sprayable Holdings, Inc. Methods and compositions for transdermal delivery
CN114522152A (en) 2015-03-11 2022-05-24 艾利斯达医药品公司 Use of antistatic materials in airways for hot aerosol condensation processes
SI3551189T1 (en) 2016-12-09 2024-03-29 Alexza Pharmaceuticals, Inc. Alprazolam for use in treating epilepsy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB903866A (en) * 1961-05-09 1962-08-22 Dausse Lab Therapeutic preparations containing 7-substituted theophylline derivatives
JPH01221313A (en) * 1988-02-29 1989-09-04 Hayashi Teruaki Sublimation-releasable medicine composition and releasing system thereof
US5525329A (en) * 1992-05-21 1996-06-11 The Johns Hopkins University Inhibition of phosphodiesterase in olfactory mucosa
WO2001013957A2 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
WO2001041732A1 (en) * 1999-12-06 2001-06-14 Gore Stanley L Compositions and methods for intranasal delivery of active agents to the brain
WO2001080829A2 (en) * 2000-04-20 2001-11-01 Bristol-Myers Squibb Company Taste masking coating composition

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1063512A (en) 1962-11-30 1967-03-30 Benger Lab Ltd Aerosols
USRE30285E (en) 1972-05-22 1980-05-27 Spraying devices, in particular nebulizing devices
US3949743A (en) 1973-03-19 1976-04-13 Schick Incorporated Medicated vapor production method and apparatus
US3982095A (en) 1973-10-04 1976-09-21 Searle Cardio-Pulmonary Systems Inc. Respiratory humidifier
US4303083A (en) 1980-10-10 1981-12-01 Burruss Jr Robert P Device for evaporation and inhalation of volatile compounds and medications
DE3116951C2 (en) 1981-04-29 1984-12-20 Drägerwerk AG, 2400 Lübeck Device for adding liquid anesthetics to the breathing gas to be supplied to the patient
DE3224849A1 (en) 1982-07-02 1984-01-05 Plantorgan Werk Heinrich G.E. Christensen, KG, 2903 Bad Zwischenahn STEAM INHALER
JPS63500175A (en) 1985-05-22 1988-01-21 リポソ−ム　テクノロジ−，インコ−ポレイテツド Liposome inhalation method and inhalation system
US4735217A (en) 1986-08-21 1988-04-05 The Procter & Gamble Company Dosing device to provide vaporized medicament to the lungs as a fine aerosol
US4734560A (en) 1987-01-20 1988-03-29 Medical Enterprises, Ltd. Vaporizing unit
US4906417A (en) 1988-02-08 1990-03-06 Associated Mills Inc. Humidifier
US4853517A (en) 1988-03-28 1989-08-01 John G. Bowen Vaporizing unit
EP0358114A3 (en) 1988-09-08 1990-11-14 R.J. Reynolds Tobacco Company Aerosol delivery articles utilizing electrical energy
US4917119A (en) 1988-11-30 1990-04-17 R. J. Reynolds Tobacco Company Drug delivery article
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US4941483A (en) 1989-09-18 1990-07-17 R. J. Reynolds Tobacco Company Aerosol delivery article
CA2070823C (en) 1989-12-05 1999-01-12 William H. Ii Frey Neurologic agents for nasal administration to the brain
GB2239807A (en) 1990-01-09 1991-07-17 Boc Group Plc Anaesthetic vaporiser
US5099861A (en) 1990-02-27 1992-03-31 R. J. Reynolds Tobacco Company Aerosol delivery article
US5366770A (en) 1990-04-17 1994-11-22 Xingwu Wang Aerosol-plasma deposition of films for electronic cells
EP0469797B2 (en) 1990-08-02 2001-12-12 Datex-Ohmeda Inc. Anaesthetic vaporiser
DE69229070T2 (en) 1991-02-09 1999-11-18 B S D Bio Science Dev Snc Di O Antireactive anti-asthmatic effects of acetylsalicylic acid by inhalation
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5639441A (en) * 1992-03-06 1997-06-17 Board Of Regents Of University Of Colorado Methods for fine particle formation
ATE204750T1 (en) 1992-06-12 2001-09-15 Teijin Ltd PHARMACEUTICAL PREPARATION FOR USE IN THE RESPIRATORY CIRCULATION
AU5358694A (en) 1992-10-28 1994-05-24 Charles A. Rosen Method and devices for delivering drugs by inhalation
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US5694919A (en) 1993-01-29 1997-12-09 Aradigm Corporation Lockout device for controlled release of drug from patient-activated dispenser
US5724957A (en) 1993-01-29 1998-03-10 Aradigm Corporation Intrapulmonary delivery of narcotics
US5507277A (en) 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
US5915378A (en) 1993-01-29 1999-06-29 Aradigm Corporation Creating an aerosolized formulation of insulin
US5558085A (en) 1993-01-29 1996-09-24 Aradigm Corporation Intrapulmonary delivery of peptide drugs
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
KR100314138B1 (en) 1993-06-29 2001-12-28 마틴 보게스 로버트 Metering device
US5388574A (en) 1993-07-29 1995-02-14 Ingebrethsen; Bradley J. Aerosol delivery article
US5456247A (en) 1993-08-26 1995-10-10 Iowa State University Research Foundation, Inc. Method for delivering drugs soluble in a vaporization vehicle
FI98270C (en) 1993-11-29 1997-05-26 Instrumentarium Oy Method and apparatus for evaporation of anesthetic agent
US6102036A (en) 1994-04-12 2000-08-15 Smoke-Stop Breath activated inhaler
MA23588A1 (en) 1994-06-23 1995-12-31 Procter & Gamble TREATMENT OF NEED FOR NICOTINE AND / OR SMOKING-RELATED SYNDROME
US5456677A (en) * 1994-08-22 1995-10-10 Spector; John E. Method for oral spray administration of caffeine
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
EP1177807A3 (en) 1994-10-28 2003-10-22 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
JPH11502845A (en) 1995-03-31 1999-03-09 アラディグム コーポレーション Pulmonary delivery of hematopoietic agents
US5758637A (en) 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5649554A (en) 1995-10-16 1997-07-22 Philip Morris Incorporated Electrical lighter with a rotatable tobacco supply
US6041777A (en) * 1995-12-01 2000-03-28 Alliance Pharmaceutical Corp. Methods and apparatus for closed-circuit ventilation therapy
SE9504580L (en) 1995-12-21 1997-06-22 Siemens Elema Ab Procedure for gasification of an anesthetic fluid and a carburetor
US5900416A (en) * 1996-02-01 1999-05-04 Anthea Enterprises Incorporated Aqueous caffeine dosage forms
EP0955885A1 (en) 1996-02-05 1999-11-17 Aradigm Corporation Ventilation imaging using a fine particle aerosol generator
US5743251A (en) 1996-05-15 1998-04-28 Philip Morris Incorporated Aerosol and a method and apparatus for generating an aerosol
EP0857431B1 (en) 1996-06-17 2003-03-12 Japan Tobacco Inc. Flavor generating product and flavor generating tool
GB9613015D0 (en) 1996-06-21 1996-08-28 Reckitt & Colman Inc Device
US6089857A (en) 1996-06-21 2000-07-18 Japan Tobacco, Inc. Heater for generating flavor and flavor generation appliance
US6694975B2 (en) 1996-11-21 2004-02-24 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5906202A (en) 1996-11-21 1999-05-25 Aradigm Corporation Device and method for directing aerosolized mist to a specific area of the respiratory tract
ATE287257T1 (en) 1997-01-16 2005-02-15 Massachusetts Inst Technology PREPARATION OF PARTICLE-CONTAINING MEDICINAL PRODUCTS FOR INHALATION
US6461591B1 (en) 1997-02-05 2002-10-08 Jago Research Ag Medical aerosol formulations
US5829435A (en) 1997-02-24 1998-11-03 Aradigm Corporation Prefilter for prevention of clogging of a nozzle in the generation of an aerosol and prevention of administration of undesirable particles
US6090212A (en) 1997-08-15 2000-07-18 Micro C Technologies, Inc. Substrate platform for a semiconductor substrate during rapid high temperature processing and method of supporting a substrate
EP1019023B1 (en) 1997-09-29 2003-05-07 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
CA2322805C (en) 1998-03-05 2005-09-13 Nippon Shinyaku Co., Ltd. Fat emulsions for inhalational administration
AU4680699A (en) 1998-06-12 1999-12-30 Aradigm Corporation Methods of delivering aerosolized polynucleotides to the respiratory tract
US6095153A (en) 1998-06-19 2000-08-01 Kessler; Stephen B. Vaporization of volatile materials
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
WO2000000215A1 (en) 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US6255334B1 (en) 1998-10-30 2001-07-03 Pfizer Inc 5HT 1 receptor agonists and metoclopramide for the treatment of migraine
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6070575A (en) 1998-11-16 2000-06-06 Aradigm Corporation Aerosol-forming porous membrane with certain pore structure
WO2000047203A1 (en) 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
US6591839B2 (en) 1999-02-17 2003-07-15 Dieter Meyer Filter material for reducing harmful substances in tobacco smoke
EP1173482A1 (en) 1999-04-27 2002-01-23 Eli Lilly And Company Insulin crystals for pulmonary administration
BR0010262A (en) 1999-05-03 2002-01-15 Battelle Memorial Institute Composition to form an aerosol, process for preparing and aerosolizing a composition, and aerosol generating device
US6428769B1 (en) 1999-05-04 2002-08-06 Aradigm Corporation Acute testosterone administration
EP1192009B1 (en) 1999-06-11 2013-05-01 Aradigm Corporation Method for producing an aerosol
WO2001005459A1 (en) 1999-07-16 2001-01-25 Aradigm Corporation System for effecting smoke cessation
CZ20021086A3 (en) 1999-09-30 2002-10-16 Neurogen Corporation Alkylenediamine substituted heterocycles
AU3400501A (en) 2000-02-28 2001-09-12 Vectura Ltd Improvements in or relating to the delivery of oral drugs
US6632047B2 (en) 2000-04-14 2003-10-14 Board Of Regents, The University Of Texas System Heater element for use in an in situ thermal desorption soil remediation system
CA2410577A1 (en) 2000-05-23 2001-12-13 The Trustees Of Columbia University In The City Of New York Method for treating respiratory disorders associated with pulmonary elastic fiber injury
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
EP1383376A4 (en) 2001-03-19 2006-03-08 Praecis Pharm Inc Pharmaceutical formulations for sustained release
US20030004142A1 (en) 2001-04-18 2003-01-02 Prior Christopher P. Use of NSAIDs for prevention and treatment of cellular abnormalities of the lung or bronchial pathway
US6759029B2 (en) * 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US7585493B2 (en) * 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
EP1392260A2 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of benzodiazepines through an inhalation route
US20070122353A1 (en) * 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US20030118512A1 (en) * 2001-10-30 2003-06-26 Shen William W. Volatilization of a drug from an inclusion complex
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
CA2447519C (en) * 2001-05-24 2008-09-16 Alexza Molecular Delivery Corporation Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US20030051728A1 (en) * 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US7645442B2 (en) * 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US6805853B2 (en) 2001-11-09 2004-10-19 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
US6802825B2 (en) * 2001-07-03 2004-10-12 Coopersurgical, Inc. Access catheter apparatus for use in minimally invasive surgery and diagnostic procedures in the uterus and fallopian tubes
JP2006514934A (en) * 2002-11-26 2006-05-18 アレックザ ファーマシューティカルズ， インコーポレイテッド Use of loxapine or amoxapine for the manufacture of drugs for the treatment of pain
US20040105818A1 (en) * 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
AU2003295823B2 (en) * 2002-11-26 2009-11-05 Alexza Pharmaceuticals, Inc. Treatment of headache with antipsychotics delivered by inhalation
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US7913688B2 (en) * 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
JP2007516404A (en) * 2003-05-21 2007-06-21 アレックザ ファーマシューティカルズ， インコーポレイテッド Optically or electrically ignited built-in heating unit and drug supply unit using the same
US20050037506A1 (en) * 2003-08-04 2005-02-17 Alexza Molecular Delivery Corporation Methods of determining film thicknesses for an aerosol delivery article
CA2534566A1 (en) * 2003-08-04 2005-02-24 Alexza Pharmaceuticals, Inc. Substrates for drug delivery device and methods of preparing and use
WO2005061033A1 (en) * 2003-12-15 2005-07-07 Alexza Pharmaceuticals, Inc. Treatment of breakthrough pain by drug aerosol inhalation
WO2005059804A2 (en) * 2003-12-16 2005-06-30 Alexza Pharmaceuticals, Inc. Methods for monitoring severity of panic attacks and other rapidly evolving medical events in real-time
US20060014737A1 (en) * 2004-03-09 2006-01-19 Varghese John Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
EP1781360A1 (en) * 2004-08-12 2007-05-09 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
US20060032496A1 (en) * 2004-08-12 2006-02-16 Alexza Molecular Delivery Corporation Inhalation actuated percussive ignition system
EP1809240A4 (en) * 2004-10-12 2010-06-16 Alexza Pharmaceuticals Inc Cardiac safe, rapid medication delivery

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB903866A (en) * 1961-05-09 1962-08-22 Dausse Lab Therapeutic preparations containing 7-substituted theophylline derivatives
JPH01221313A (en) * 1988-02-29 1989-09-04 Hayashi Teruaki Sublimation-releasable medicine composition and releasing system thereof
US5525329A (en) * 1992-05-21 1996-06-11 The Johns Hopkins University Inhibition of phosphodiesterase in olfactory mucosa
WO2001013957A2 (en) * 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
WO2001041732A1 (en) * 1999-12-06 2001-06-14 Gore Stanley L Compositions and methods for intranasal delivery of active agents to the brain
WO2001080829A2 (en) * 2000-04-20 2001-11-01 Bristol-Myers Squibb Company Taste masking coating composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 198941, Derwent World Patents Index; Class B07, AN 1989-297792, XP002230849 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2081431A1 (en) * 2006-11-13 2009-07-29 Intra-Cellular Therapies, Inc. Organic compounds
EP2081431A4 (en) * 2006-11-13 2011-01-19 Intra Cellular Therapies Inc Organic compounds
US9198924B2 (en) 2006-11-13 2015-12-01 Intra-Cellular Therapies, Inc. Organic compounds
WO2013006809A3 (en) * 2011-07-06 2013-06-13 Breathable Foods, Inc. Aerosolizing particles
WO2015006465A1 (en) * 2013-07-10 2015-01-15 Ahkeo Ventures LLC Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same
US10632266B2 (en) 2013-07-10 2020-04-28 Ahkeo Ventures LLC Inhalable compositions comprising caffeine, methods of use and an apparatus for using the same

Also Published As

Publication number Publication date
CA2460343A1 (en) 2003-07-17
US7488469B2 (en) 2009-02-10
US7078016B2 (en) 2006-07-18
US20060257328A1 (en) 2006-11-16
US20030138382A1 (en) 2003-07-24
EP1446102A1 (en) 2004-08-18
AU2002363947A1 (en) 2003-07-24

Similar Documents

Publication Publication Date Title
US7488469B2 (en) Delivery of caffeine through an inhalation route
US7045119B2 (en) Delivery of diazepam through an inhalation route
US7060255B2 (en) Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US6780399B2 (en) Delivery of stimulants through an inhalation route
AU2002310085A1 (en) Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
WO2002094244A2 (en) Delivery of benzodiazepines through an inhalation route
WO2002094233A1 (en) Delivery of antiemetics through an inhalation route
WO2002094229A1 (en) Delivery of muscle relaxants through an inhalation route
WO2002094239A1 (en) Delivery of diphenhydramine through an inhalation route

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2460343

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002798463

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002798463

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002798463

Country of ref document: EP